LD-HA方案在急性髓系白血病治疗中的应用  

The application of LD-HA regimen in the therapy of acute myeloid leukemia

作　　者：李丹慧[1] 李国辉[1] 梁英民[1] 

机构地区：[1]第四军医大学唐都医院血液科,陕西西安710038

出　　处：《现代肿瘤医学》2016年第3期482-485,共4页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:81100354)

摘　　要：上世纪80年代,由于缺乏有效的支持治疗(如抗生素、输血、细胞因子等),小剂量化疗药物治疗急性髓系白血病(acute myeloid leukemia,AML)成为当时的一个研究热点,特别是小剂量阿糖胞苷化疗方案的应用,取得了良好效果。1984年Body等体外证明了小剂量三尖杉酯碱有诱导HL-60细胞分化成熟的作用。1985年黄昌亮等国内外率先报告了LD-HA方案治疗AML的疗效,目前已成为不适合标准治疗方案的急性髓系白血病患者主要选择性方案之一,本文就LD-HA临床应用、疗效及存在问题作一综述。In the 1980s, because of the lack of effective supportive care （such as antibiotics, blood transfusions, cytokines, etc. ） ,low - dose chemotherapy for acute myeloid leukemia （AML） became a hot topic, especially chemotherapy consisted of low - dose cytarabine achieved good results. In 1984, Body demonstrated low - dose harringtonine can induce HL -60 cell differentiation and maturation in vitro. In 1985, Huang CL, eet. reported the efficacy of LD - HA regimen in AML at home and abroad,and now LD - HA regimen has become the major choice of the acute myeloid leukemia patients who can not tolerated standard treatment regimen. This paper is to review the clinical applications, efficacy and problems of LD - HA.

关 键 词：小剂量HA 急性髓系白血病 治疗 

分 类 号：R733.7[医药卫生—肿瘤]